PTN 株価分析 — Palatin Technologies, Inc. Common Stock (Healthcare >> Biotechnology)
PTN に関するよくある質問
PTNのPER(株価収益率)は?
Palatin Technologies, Inc. Common Stock(PTN)は現在PER 3.05倍で取引されています。
PTNのROE(自己資本利益率)は?
Palatin Technologies, Inc. Common StockのROEは-59.00%です。
PTNの配当利回りは?
Palatin Technologies, Inc. Common Stockの配当利回りは0.00%です。
PTNの品質スコア(Quality Score)は?
当社のAIはPTNの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PTNは今が買い時ですか?
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PTNはどのセクターに属しますか?
Palatin Technologies, Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PTN AI Analysis Summary
Our AI summary for PTN: Palatin Technologies, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.05, ROE of -59.00%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.94
Price
-0.07
(-0.87%)
Day Change
|
|
|---|
PTN, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
55% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.94 |
| PBV / Sector |
1.35 / 44,105.10
GOOD
|
| Earning Per Share | -3.48 |
| PE / Sector |
3.05 / 19.37
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 1.06
GREAT
|
| Average 1M Daily Value |
0.09 M
GREAT
|
| Average 1W Daily Value |
0.08 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:32 |
| Symbol | PTN |
| Name | PALATIN TECHNOLOGIES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.25 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11 Deer Park Drive, Monmouth Junction, NJ, United States, 08512
Phone: 609 495 2200
Website: https://palatin.com
Sector: Healthcare >> Biotechnology
Description: Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google